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Abstract
Background: Myosin heavy chain 7 related myopathies are rare disorders characterized by a wide phenotypic
spectrum and heterogeneous pathological features. In the present study, we performed clinical, morphological,
genetic and imaging investigations in three relatives affected by autosomal dominant distal myopathy. Whilst
earlier traditional Sanger investigations had pointed to the wrong gene as disease causative, next-generation
sequencing allowed us to obtain the definitive molecular genetic diagnosis in the family.
Case presentation: The proposita, being found to harbor a novel heterozygous mutation in the RYR1 gene
(p.Glu294Lys), was initially diagnosed with core myopathy. Subsequently, consideration of muscle magnetic resonance
imaging (MRI) features and extension of family study led this diagnosis to be questioned. Use of next-generation
sequencing analysis identified a novel mutation in the MYH7gene (p.Ser1435Pro) that segregated in the affected family
members.
Conclusions: This study identified a novel mutation in MYH7 in a family where the conclusive molecular diagnosis was
reached through a complicated path. This case report might raise awareness, among clinicians, of the need to interpret
NGS data in combination with muscle MRI patterns so as to facilitate the pinpointing of the main molecular etiology in
inherited muscle disorders.
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Background
More than 200 different dominantly inherited mutations
in MYH7, encoding the human slow/β myosin heavy
chain, have been identified and associated with a variety
of clinical myosinopathies, including hypertrophic (MIM
192600) or dilated cardiomyopathy with left ventricular
non-compaction (MIM 613426), myosin storage myop-
athy (MIM 608358) and Laing distal myopathy (LDM)
(MIM 160500) [1, 2]. Additional related clinical syn-
dromes include congenital myopathies with features of
multi-minicores (MMC) or fiber type disproportion
(CFTD) in skeletal muscle, and combinations of heart
and muscle involvement [3, 4]. The clinical manifesta-
tions may range from asymptomatic to limb-girdle,
scapuloperoneal or distal muscle involvement [3];
congenital as well as late-onset manifestations have also
been described and the clinical phenotype can vary
within a single family [5].
Typical cases of LDM are characterized by early-onset
ankle dorsiflexor weakness, the “hanging big toe” sign
and normal or moderately elevated serum creatine
kinase (CK) levels. Dropped fingers pattern of weakness,
involvement of neck flexor and abdominal and facial
muscles might occur [6]. As the disease progresses, vari-
able clinical findings include quadriceps atrophy, ankle
retraction, pes cavus, scoliosis, claw toes, a high-arched
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palate and myalgia. EMG shows a combination of myo-
pathic and neurogenic features [3], and muscle biopsies
can reveal (in addition to the subsarcolemmal accumula-
tion that is a characteristic finding in myosin storage my-
opathy) various and unspecific findings, such as CFTD,
cores or MMC, and mitochondrial abnormalities [6].
We describe the clinical and myoimaging data collected
in a family with an autosomal dominant (AD) distal myop-
athy due to a heterozygous mutation in MYH7, which was
initially unrecognized due to incorrect attribution of the
phenotype to a variant in RYR1.
Methods
The index case and her relatives underwent full neuro-
muscular assessment, and written informed consent for
molecular genetic testing was obtained prior to genomic
DNA purification from blood. Mutation screening of the
proposita used an amplicon-based Sanger sequencing
method focused on RYR1 (NM_000540), as reported [7].
We also used MotorPlex [8], a targeted next-generation
sequencing (NGS) panel, to investigate the coding regions
of 92 genes responsible of non-syndromic muscle disor-
ders. Variant annotation was performed as described [8]
and analyses of polymorphic human variations included
dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/),
EVS6500 (evs.gs.washington.edu), ClinVar (http://
www.ncbi.nlm.nih.gov/clinvar/), ExAC Browser (exac.-
broadinstitute.org/), and 1000G dataset (www.1000geno-
mes.org). The damaging effects of the SNVs were
evaluated in silico using Mutation Taster (www.muta-
tiontaster.org), PolyPhen-2 (Polymorphism Phenotyping
v2) (genetics.bwh.harvard.edu/pph2/), SIFT (SIFT, http://
sift.jcvi.org), and PANTHER (http://www.pantherdb.org/).
Case presentation
Table 1 summarizes the clinical and morphological fea-
tures, genetic data, and electrophysiology results of the
living members in generations III and IV in this family.
From the age of 30 years, the proposita (case III.4 in
Fig. 1 a) showed a prevalently distal muscle phenotype
characterized by stepping gait with progressive pes
cavus, mild proximal muscle weakness in the lower
limbs, and scoliosis. Upper limbs were spared. Her CK
levels had always been in the normal range and her car-
diac and respiratory functions were normal. At the age
of 47 years, muscle biopsy did not reveal aggregates,
showed fiber size variability, increased internal nuclei
and histochemical evidence of eccentric “core-like le-
sions” [9], mainly in type I fibers (Fig. 1 b). The ATPase
stains (pH 4.3, 4.6, 9.4) evidenced a slight predominance
of type I fiber which were hypotrophic (see Additional
file 1: Figure S1). At that time, the possibility of a core
myopathy prompted us to analyze RYR1 and we detected
a heterozygous c.880G > A:p.(Glu294Lys). This mutation
was predicted to be deleterious, and it was absent in hu-
man polymorphic databases, and in 200 in-house healthy
Italian control chromosomes.
The family history was significant for similar muscle
weakness in four relatives. Careful review of the
medical notes in two patients (I.2 and II.2, both de-
ceased) revealed that they had experienced foot drop
while walking. In case III.2, a complete neurological
examination and the observation of muscle biopsy
findings suggestive of core myopathy suggested a
disorder similar to his youngest sister. Unexpectedly,
however, case III.2, did not harbor the c.880G >
A:p.(Glu294Lys) in RYR1. Thus, the molecular diagno-
sis in this family remained undefined for several years
until case IV.1 (the younger daughter of III.2), aged
33 years, complained of muscle weakness and sought
genetic counseling. This patient displayed a less pro-
gressive muscular phenotype than her older relatives,
tested negative for the mutation in RYR1, and refused
to undergo a muscle biopsy.
To reconcile clinical and morphological findings with
molecular data in this family, we asked III.2, III.4, and
IV.1 to undergo muscle MRI of the thighs and calves
(1.5T MR System, Signa Horizon LX, Healthcare GE,
USA). Meanwhile, we used MotorPlex [8] to analyze in
case III.4 a large set of genes that cause known forms
of non-syndromic muscle disorders. Conventional T1-
weighted spin echo images in case III.4 at the age of
61 years revealed almost complete fatty substitution of
the tibialis anterior muscles with sparing of gastrocnemii
and solei (Fig. 2 a), whereas there were no alterations in
the thigh muscles (not shown). Likewise, muscle MRI in
case III.2 at the age of 68 years documented involvement
of the tibialis anterior and extensor digitorum longus
(Fig. 2 b) with relative sparing of the thigh muscles (not
shown). Case IV.1 showed discrete fatty degeneration of
the tibialis anterior muscles. A follow-up MRI in III.2
and III.4 showed a substantially stable picture with
limited additional deterioration (Fig. 2 c–h) except for
the finding of involvement of the adductor magnus,
vastus intermedius (Fig. 2f ) and medial gastrocnemius
(Fig. 2g) in III.2. In addition, neck and upper limb
muscle MRI scans revealed bilateral involvement of
the sternocleidomastoid and deltoid muscles in III.2
(Fig. 2h) but not in III.4.
The rather homogeneous myoimaging patterns in
three affected relatives served to prioritize the >200 gene
variants with a predicted deleterious significance that
had emerged from the MotorPlex panel in case III.4.
This strategy pinpointed only the novel heterozygous
c.4303 T > C:p.(Ser1435Pro) in MYH7 (NM_000257)
(Polyphen severity score of 1.000; SIFT score 0, Dam-
aging) as the possible causative mutation. Sanger se-
quencing confirmed the presence of the mutation
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Table 1 Summary of findings in the living members in this family


























III.2 30 68 Severe distal AT contractures pes cavus No Yes Slow Yes Yes No Hypo No Myopathic
III.3 - 66 - - - - - - - - - - - -
III.4 35 61 Severe distal;
mild proximal
AT contractures pes cavus Yes No Slow Yes Yes No Hypo Yes Myopathic
IV.1 a 33 34 Moderate
distal
No pes cavus No No Slow - - - - NA Myopathic
IV.2 - 27 - - - - - - - - - - - -














Fig. 1 Family tree, genetic and skeletal muscle features in a patient harboring a novel mutation in MYH7. a Pedigree of the family. Circles are
women and squares are men. The RYR1 and MYH7 genotypes of the affected individuals are also indicated. WT indicates normal sequence. b
Muscle biopsy findings in patients III.4 (upper panel, final magnification x500) and III.2 (lower panel, x250). Light microscopy of sections stained
with NADH-tetrazolium reductase showed subtle eccentric disarray of the intermyofibrillar network or eccentric cores. c Electropherogram of the
region flanking the c.4303 T > C:p.(Ser1435Pro) mutation in the MYH7 gene. The arrow indicates the nucleotide change in case III.4 (P1) when
compared to a normal control (WT). The mutated codon is boxed
Fig. 2 Myo-imaging in family members. Muscle MRI findings at calf level in III.4 (a) and III.2 (b) were obtained using conventional T1-weighted
spin-echo transverse images. Both scans show the selective involvement of the tibialis anterior and, in III.2, of the extensor digitorium longus with
sparing of gastrocnemii and soleus. Follow-up muscle MRI after 3 years in III.4 (c–e) and III.2 (f–h) obtained using conventional T1-weighted
spin-echo transverse images at thigh (c, f), calf (d, g) and upper girdle (e–h) level. The findings in III.4 are almost stable whereas in III.2 it is possible to
observe the additional involvement of the adductor magnus and vastus intermedius at thigh level (f) and of the medial gastrocnemius at calf level (g).
The scans of the upper girdle reveal involvement of the deltoid and sternocleidomastoid muscles
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(Fig. 1c) lying in the myosin tail domain of myosin-7 in
the three living affected family members and ruled
out its presence in the healthy III.3 and IV.2, and in
300 in-house Italian control chromosomes.
Discussion
This short report provides an illustration of how a
modern multidisciplinary approach can be used to ob-
tain a correct genetic diagnosis in neuromuscular disor-
ders and offers at least two interconnected learning
points. First, it revealed an additional value of NGS
tools, that is, the strategic help in revising long-term
diagnoses in muscular disorders [10] as already done in
other neurogenetic conditions [11]. In the index patient
a variant detected in a gene associated with core myop-
athies (RYR1) was initially taken to be disease-causative,
given that accepted in silico criteria for protein damage
were met and there was morphological evidence of core
myopathy in her muscle biopsy. However, since it was
subsequently found that other affected family members
did not carry the same mutation, we used NGS to
expand the genetic analyses in combination with muscle
MRI examinations to rank genetic variants. The
p.Ser1435Pro in MYH7 ― the most N-terminal muta-
tion in the myosin-7 rod domain so far associated with
LDM [6] ― finally reconciled genotype with phenotype.
With hindsight, however, had the family undergone a
more complete clinical assessment at the time of the
initial evaluations, they could have already been diag-
nosed with a dominantly-inherited distal myopathy.
Core-like features, the findings of fiber type dispropor-
tion in muscle biopsy, or possible insights from ultra-
structural investigations as described [5], combined
with weak ankle dorsiflexion should have warned on a
distal phenotype related to myosin-7, as shown before
[9], even prior the use of muscle MRI. Onset of a
hypertrophic cardiomyopathy in one member (Table 1)
was a further “red flag” that could have directed the
genetic analysis towards MYH7 and thus reduced the
diagnostic “odyssey” for this family. The second learning
point is related to the critical value of muscle MRI
when targeted NGS is used in neuromuscular centers.
Although gene panels such as MotorPlex [8] are
increasingly being used in clinical practice [12], they
introduce a new level of complexity, identifying mul-
tiple potential disease-associated variants that often
have no clear-cut relationships with the clinical diag-
nosis. In the present family with a dominant transmis-
sion of core myopathy and distal muscle involvement,
MRI clearly documented a preferential involvement of
anterior leg muscles orienting toward a diagnosis of
LDM and contributing to rank a variant in MYH7 as
disease causative.
Conclusions
Our clinical report further corroborates how available
modern tools can be used effectively in the era of clinical
genomic medicine. Thus, it might raise awareness, among
clinicians, of the need to interpret NGS data in combin-
ation with muscle MRI patterns so as to facilitate the
pinpointing of the main molecular etiology in inherited
muscle disorders.
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